Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,246.3
-13.7 (-0.42%)

 

  • STI Straits Times Index
    3,246.3
    -13.7 (-0.42%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,520.0
    4.0 (0.27%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,550.1
    -256.9 (-1.08%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,361.4
    -32.8 (-0.97%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 847.3M
  • Value: 2,125.0M
  • Rise: 131
  • Fall: 176
  • Unch: 461

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Singtel2.460-0.040
Genting Sing0.720-0.005
CapLand IntCom T1.940-0.020
Sembcorp Marine0.082-
Mapletree Log Tr1.690-0.030
Mapletree Com Tr1.810-0.040
Mapletree NAC Tr1.080-0.010
Jiutian Chemical0.085+0.002
ThaiBev0.650+0.005
Keppel Corp5.610+0.320

World Indices

World Indices
Name Last Change
Nasdaq 13,352.8 -189.3
HSI 23,550.1 -256.9
HSCEI 8,210.3 -81.0
Jakarta 6,645.5 +34.4
Nikkei 225 26,717.3 +547.0
SSE Comp 3,361.4 -32.8
Shanghai A 3,522.5 -34.5
Shanghai B 280.7 +1.7
KOSPI 2,663.3 +48.9

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

VTV THERAPEUTICS INC VTV THERAPEUTICS, INC. CLASS A
Updated on 27 Jan 2022 (End of trading day)
Last (USD): 0.699 Change: -0.035 High: 0.770 Remarks: -
Change (%): -4.81 Low: 0.670
Open 0.737 Yesterday's Close 0.7344
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 374,695 Cumulative Value

Company Background

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.09439 Trailing EPS (USD) b -0.05342 NAV (USD) c -0.2393
PE a - Trailing PE d - Price / NAV c -2.9214
Dividend Yield (%) e - Cash In Hand (USD) f 0.2173 Issued & Paid-up Shares g 66,942,800
Piotroski F Score 3 Market Cap (M) 62.945 Free Float (%) 45.3
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i 47,150.000
Net Earnings Growth (%) j 67.185 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 11 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.070
-9.09 %
10 Days --0.180
-20.47 %
20 Days --0.296
-29.74 %
Medium Term Return 3 Months --0.731
-51.11 %
6 Months --1.221
-63.59 %
1 Year --1.341
-65.73 %
Long Term Return 2 Years --1.511
-68.37 %
3 Years --2.111
-75.12 %
5 Years --5.031
-87.80 %
Annualised Return Annualised --
-34.34 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference VTV THERAPEUTICS INC NASDAQ 62.945 - - -2.9214 -
Industry Pharmaceuticals: Major NASDAQ 1,976.093 79.073 91.614 2.5875 0.029
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 184,440.576 57.710 125.384 4.6407 -
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 133,583.563 9.516 19.290 1.7813 2.561
Local Peer ROYALTY PHARMA PLC NASDAQ 23,485.490 24.087 30.001 4.0541 0.496
Local Peer VIATRIS INC NASDAQ 17,645.000 - - 0.8346 -
Local Peer REPLIGEN CORP NASDAQ 9,789.935 163.367 82.352 5.7075 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 6,760.554 948.464 22.950 5.8764 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 6,486.679 - - 5.6333 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 5,468.293 - - 24.2100 -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 4,409.103 - - 4.4771 -
Local Peer APELLIS PHARMACEUTICALS INC NASDAQ 3,574.810 - - -62.3555 -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 3,467.408 - - 5.5119 -
Local Peer CUREVAC NV NASDAQ 3,120.044 - - - -
Other Local Peers KARUNA THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), EQRX INC (NASDAQ), OPKO HEALTH INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ERASCA INC (NASDAQ), AMYLYX PHARMACEUTICALS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), QUANTERIX CORPORATION (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ICOSAVAX INC (NASDAQ), CINCOR PHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), PETIQ INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), PHARVARIS NV (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), KRONOS BIO INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), TRICIDA INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), EVOLUS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ALLAKOS INC (NASDAQ), GRITSTONE BIO INC<